513 related articles for article (PubMed ID: 29177611)
21. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
Yoon YK; Kim JH; Sohn JW; Yang KS; Kim MJ
Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
[TBL] [Abstract][Full Text] [Related]
22. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
[TBL] [Abstract][Full Text] [Related]
23. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.
Namikawa H; Yamada K; Fujimoto H; Oinuma KI; Tochino Y; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
Intern Med; 2017; 56(14):1807-1815. PubMed ID: 28717075
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
[TBL] [Abstract][Full Text] [Related]
25. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
[TBL] [Abstract][Full Text] [Related]
26. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
[TBL] [Abstract][Full Text] [Related]
27. Impact of a hospital sepsis management protocol on the selection of empirical antibiotics in infectious disease consultations.
Özden A; Dalgıç B; Demir M; Hazırolan G; Uzun Ö; Metan G
J Chemother; 2024 May; 36(3):190-197. PubMed ID: 38131316
[TBL] [Abstract][Full Text] [Related]
28. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G
BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488
[TBL] [Abstract][Full Text] [Related]
29. Initial empirical antibiotics of non-carbapenems for ESBL-producing E. coli and K. pneumoniae bacteremia in children: a retrospective medical record review.
Park S; So H; Kim MN; Lee J
BMC Infect Dis; 2022 Nov; 22(1):866. PubMed ID: 36404302
[TBL] [Abstract][Full Text] [Related]
30. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae.
Katip W; Yoodee J; Uitrakul S; Oberdorfer P
Sci Rep; 2021 Jan; 11(1):18. PubMed ID: 33420122
[TBL] [Abstract][Full Text] [Related]
32. Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options.
Sethaphanich N; Santanirand P; Rattanasiri S; Techasaensiri C; Chaisavaneeyakorn S; Apiwattanakul N
Pediatr Int; 2016 May; 58(5):338-46. PubMed ID: 26513341
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
Haruki Y; Hagiya H; Haruki M; Sugiyama T
J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
[TBL] [Abstract][Full Text] [Related]
34. Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis.
Wu UI; Chen WC; Yang CS; Wang JL; Hu FC; Chang SC; Chen YC
Int J Infect Dis; 2012 Jan; 16(1):e47-52. PubMed ID: 22055248
[TBL] [Abstract][Full Text] [Related]
35. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
[TBL] [Abstract][Full Text] [Related]
36. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
[TBL] [Abstract][Full Text] [Related]
37. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis.
Yang CC; Li SH; Chuang FR; Chen CH; Lee CH; Chen JB; Wu CH; Lee CT
BMC Infect Dis; 2012 Sep; 12():206. PubMed ID: 22947300
[TBL] [Abstract][Full Text] [Related]
38. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters.
Cheng WL; Hsueh PR; Lee CC; Li CW; Li MJ; Chang CM; Lee NY; Ko WC
J Microbiol Immunol Infect; 2016 Apr; 49(2):208-15. PubMed ID: 25070279
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
[TBL] [Abstract][Full Text] [Related]
40. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
